Thelansis

Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition, often overlooked, characterized by low circulating alpha-antitrypsin (AAT) in the bloodstream. This condition presents as hepatic dysfunction from infancy through adulthood and chronic obstructive lung disease (specifically emphysema or bronchiectasis) in individuals over 30. People with AATD also face an elevated risk of panniculitis and C-ANCA-positive vasculitis. The expression of these symptoms can vary among individuals and families. In adults, smoking is the primary factor accelerating the development of chronic obstructive pulmonary disease (COPD). However, nonsmokers with AATD can still develop lung and liver issues and have an average life expectancy. Emphysema in children with AATD is exceedingly rare. AATD-related liver disease, seen in only a small fraction of affected children, typically presents as neonatal cholestasis. The incidence of liver disease increases with age, and adults may develop cirrhosis and f...

 Alpha-1 Antitrypsin Deficiency (AATD) is an autosomal codominant genetic condition that can result in serious lung disease in adults and/or liver disease at any age. AATD occurs when the blood is deficient in a protein called Alpha-1 antitrypsin, or AAT. The liver mainly produces AAT, which primarily protects the lungs from increased protease activity. The responsible gene, SERPINA1, is located on the long arm of chromosome 14 (14q31–32.3). According to Thelansis disease modeling data and literature review estimated, ~78000 patients with AATD in the United States in the year 2020. Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ...